Procyon Corporation
Procyon Corporation
Your view on PCYN
Overview
What the company does, where it operates, and who runs it.
About Procyon Corporation
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Justice W. Anderson
- Headquarters
- 1300 South Highland Avenue, Clearwater, FL, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Justice W. Anderson
- Headquarters
- 1300 South Highland Avenue, Clearwater, FL, US
Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems primarily in the United States.
The company offers advanced skin and wound care products, including the hydrogel wound dressing products, post op surgical kits, saline wound washes, care lotions, and barrier lotions to promote healing in wound and problematic skin conditions, as well as hand sanitizer under the AMERIGEL brand name.
It also provides Bioactive Collagen products in the form of power and matrix under the HELIX3 brand name.
In addition, the company offers wound care products, such as calcium alginate, foam, gauze, and hyrdocolloid dressing products; and wound care kits, which include calcium alginate, collagen matrix, collagen powder, foam, and hydrogel wound care kits under the AMERX brand name, as well as compression garment line products under the EXTREMIT-EASE name.
It sells its products through distributors to institutional customers, such as hospitals, wound care clinics, nursing homes, home health agencies, physicians, and health care practitioners; and retail customers through direct sales, and internet sales, as well as through independent and retail chain drug stores.
The company was incorporated in 1987 and is based in Clearwater, Florida.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Procyon Corporation, and the rating behind it. PCYN last traded at $0.19, 108.7× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Procyon Corporation. Starting points for Procyon Corporation: P/E 108.7, beta -1.03 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Procyon Corporation. Procyon Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Procyon Corporation. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Procyon Corporation. Procyon Corporation has reported as a listed company since 1996. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Procyon Corporation valued side by side against its closest peers. Procyon Corporation is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Procyon Corporation, and how their positions are changing. At a $1.5M market value, institutional positions materially move Procyon Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Procyon Corporation executives and directors. Shares of Procyon Corporation have traded between $0.0013 and $0.19 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Procyon Corporation. Procyon Corporation is a $1.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Procyon Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Procyon Corporation. Coverage tracks Procyon Corporation within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.